Emily Holmes


Emily Holmes (Fargher) is a Research Fellow in Pharmacoeconomics at the Centre for Health Economics & Medicines Evaluation at Bangor University. Her principal research interests are the economics of adherence to medications and valuing preferences for health and social care. She is an Economics graduate of the University of Liverpool, where she developed her interest in health economics.  Upon graduating she completed a Training Fellowship in Health Economics at the University of Manchester, and gained an MSc Health Economics and Health Policy at the University of Birmingham. Prior to taking up her post at CHEME she was a Research Associate at the North West Genetics Knowledge Park and Module Leader for Health Economics on the MPHe at the University of Manchester.   

Emily joined CHEME in 2008 to work on an economic evaluation of pharmacogenetic testing for irinotecan.  She currently works on an EC funded project of adherence to medications (ABC), and a study of patient preferences and priorities for treatment options and outcomes in Epilepsy. Emily is also co-investigator on a NISCHR funded study of service user preferences for stroke services; and a staff PhD candidate.  She has ten years research experience, supports teaching activities within the department, and has published papers on: the economic evaluation of shared care; the current use of pharmacogenetics in the UK; and, patients’ and healthcare professionals’ preferences for new and existing health technologies. 

Publications (inc. Authors, title, journal, etc)

Christopher R Burton, Emily Fargher, Catrin Plumpton, Gwerfyl W Roberts, Heledd Owen and Eryl Roberts.  Investigating preferences for support with life after stroke: a discrete choice experiment.  BMC Health Services Research.  2014, 14:63. DOI: 10.1186/1472-6963-14-63

Demonceau J, Ruppar T, Kristanto P, Hughes D, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B, for the ABC project team.  Identification and assessment of adherence-enhancing interventions: a systematic literature review and meta-analysis.  Drugs. May 2013, Volume 73, Issue 6, pp 545-562.

S.T.Yeo, R.T.Edwards, E.A.Fargher, S.D.Luzio, R.L.Thomas, D.R.Owens. Preferences of people with diabetes for diabetic retinopathy screening: A discrete choice experiment. Diabetic Medicine, 2012, 29(7), 869-877 DOI: 10.1111/j.1464-5491.2012.03636.x

Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson J, Urquhart J, for the ABC project team.  A new taxonomy for describing and defining adherence to medications. BJCP

Newman WG, Payne K, Tricker K, Roberts SA, Fargher EA, Pushpakom S, Alder JE, Sidgwick GP, Payne D, Elliott RA, Heise M, Elles R, Ramsden SC, Andrews J, Houston JB, Qasim F, Shaffer J, Griffiths CE, Ray DW, Bruce I, Ollier WE; TARGET study recrtuiment team.  A Pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.  Pharmacogenomics 2011; 12(6):815-26.

Payne K, Fargher EA, Roberts S, Tricker K, Elliott RA, Ratcliffe J, Newman W.  Valuing pharmacogenetic testing services: a comparison of patients’ and healthcare professionals’ preferences.  Value in Health 2011, 14(1): 

Wickett, H and Fargher EA.  Exploring commercial weight management programmes from the perspective of females who have recently attended; a small scale qualitative study.  Practice Nursing 2010, 21(10) 252-529.

Fargher EA, Eddy C, Newman W, Elliott RA, Tricker K, Qasim F, Payne K.  Who will be responsible for pharmacogenetics in the NHS?  Pharmacogenomics: Future Medicine, 2007; 8(11): 1511-1519.

Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, & Payne K.   Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.  Journal of Clinical Pharmacy & Therapeutics, 2007, 32(2):187-195.

K Payne, W Newman, Fargher EA, Tricker K, Bruce I & WER Ollier. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology, 2007, 46(5): 727-9.  Epub 2007 Jan 25.

Davies LM, Fargher EA, Tricker K, Dawes P, Scott DL, Symmons D.  Is shared care with annual hospital review better value for money than predominantly hospital based care in patients with established rheumatoid arthritis?  Ann Rheum Dis, 2007 66(5): 658-63.  Epub 2006 Nov 23.

Published Letters

Holmes EAF, Plumpton C, Duerden M, Marson A, Hughes D.  Antiepileptic drugs:  new advice on switching between different manufacturers’ products.  BMJ Rapid Response 2013, 22 November 2013. 

Fargher EA, Hughes DA.  Involving colleagues can be challenging.  The Pharmaceutical Journal.  2 April 2011 (Vol 286).

Payne K, Fargher EA, Tricker K,  Newman B, Qasim F, Poulton K, Andrews J, Houston JB, Elliott RA, Elles RG, Ray DW, Shaffer J, Griffiths CEM, Bruce IN, Roberts SA, Ollier WER. Research Governance: What is reasonable protection? BMJ Rapid Response 2005. 

Other Reports

Burton C, Fargher EA, Plumpton C, Roberts G, Owen H, Roberts E.  Service User Preferences for Stroke Services (SUPSS).  Final report for National Institute for Social Care and Health Research (NISCHR), January 2013.

Hughes DH, Jones A, Fargher EA, Gollins S, Stuart NSA, Wagstaff J, Maughan TS, Pirmohamed M.  Cost-effectiveness of pre-prescription pharmacogenetic testing for inrinotecan.  Final report for National Institute for Social Care and Health Research (NISCHR), November 2012.

The ABC Team: Andrzejczyk A, Clyne W, De Geest S, Demonceau J, Dobbels F, Fargher E, Hughes D, Kardas P, Lewek P, Matyjaszczyk M, McLachlan S, Morrison V, Mshelia C, Parveen S, Piaszczynska A, Plumpton C, Ruppar T, Siebens K, Urquhart J, Vrijens B, White S.  Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use of medicines in Europe Final Report of the ABC Project.  June 2012.

Kardas P, Morrison V, Fargher E, Parveen S, Plumpton C, Clyne W, De Geest S, Dobbels F, Vrijens B, Urquhart J, Lewek P, Matyjaszczyk M, Hughes D. Report on the Determinants of Patient Non-Adherence with Short-Term Therapies and Treatments for Chronic Diseases in Europe.  .  ABC Project Deliverable 2.1. June 2012.

Fargher EA, Hughes D.  Report on the cost-effectiveness of interventions that promote adherence.  /ABC Project Deliverable 6.1. December 2011./

Fargher EA, Morrison V, Ruppar T, Hughes D.  Report on the conceptual framework for the determinants of non-compliance with short-term therapies and treatments for chronic diseases in Europe.  European Commission, Seventh Framework Programme.  ABC Project deliverable 3.1.  June 2010. 

Fargher EA, Payne K, Tricker K, Elliott R, Newman W.  Pharmacogenetic testing to reduce serious side effects from azathioprine in the NHS:  Current uptake and implications for prescribing practice.  Nowgen Digest 8 (2007).